✨ Free AI Report
Intercept Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Intercept Pharmaceuticals, Inc.
Company Research

Intercept Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Intercept Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nona...

Analyst-debate audio for Intercept Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Intercept Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Intercept is a mature specialty pharma asset focused on profitable extraction from a PBC franchise, now operated within a larger...

Read the full analyst-debate transcript →
Industry Orphan Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Intercept Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Intercept Pharmaceuticals, Inc. Overview

Pro stress-test →

Intercept Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). The company was acquired by Alfasigma S.p.A. in November 2023 for $19.00 per share in cash. The company's lead commercialized product is Ocaliva® (obeticholic acid).

Strategic Profile

Pro stress-test →

Intercept delivered strong double-digit growth of Ocaliva as of Q2 2023, with the company positioned as a leader in rare and serious liver disease therapeutics. The development pipeline includes INT-767, a dual FXR/TGR5 agonist, and INT-777, a TGR5 agonist. Following its acquisition by Alfasigma, the company's assets are now integrated into a larger European pharmaceutical conglomerate with expanded gastrointestinal and hepatology capabilities.

Competitive Landscape

Pro stress-test →

Intercept competes in the rare liver disease market against companies developing FXR agonists and other hepatology-focused therapeutics. The company's pipeline includes dual and single FXR/TGR5 mechanism candidates (INT-767, INT-777), positioning it against other FXR-based programs. Primary competitors in this space include Gilead Sciences (FXR program development), Viking Therapeutics (VK2735), and Madrigal Pharmaceuticals (Resmetirom for NASH).

Industry Context

Intercept Pharmaceuticals, Inc. operates in Orphan Drugs.

Key facts

Founded: 2002 · Headquarters: Morristown, New Jersey, US · Employees: unknown · Revenue: $320–$340M · Market cap: $794.7M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Intercept Pharmaceuticals, Inc..

  • Ocaliva net sales reached $83.7 million in Q2 2023, representing 17% growth over the prior year quarter
  • The FDA rejected obeticholic acid (OCA) for NASH in June 2020, determining that predicted benefit did not sufficiently outweigh predicted risks
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2023Alfasigma completed acquisition of Intercept Pharmaceuticals for $19.00 per share
  • Q2 2023Ocaliva delivered 17% year-over-year net sales growth to $83.7 million
  • +1 moreTrack every material event for Intercept Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Intercept Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Gilead Sciences Hepatology PortfolioFXR agonists and hepatology therapeutics→VK2735Dual GLP-1/GCG agonist for metabolic diseases including NASH→ResmetiromFirst-in-class non-steroidal FXR agonist for NASH→

Compare Intercept Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Intercept Pharmaceuticals, Inc. operates in Orphan Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Orphan Drugs research →
NEW · MCP server

Ask your AI assistant about Intercept Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Intercept Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Intercept Pharmaceuticals, Inc. do this quarter?”
“Is Intercept Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Intercept Pharmaceuticals, Inc. do?+
Intercept Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nona...
What is Intercept Pharmaceuticals, Inc.'s Cyborg Score?+
Intercept Pharmaceuticals, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Intercept Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Gilead Sciences Hepatology Portfolio, VK2735, Resmetirom. The full competitive landscape is in the AskCyborg report.
How can I get the full Intercept Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Intercept Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Intercept Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.